A Phase 1, Randomized, Multiple Dose, Placebo And Active Controlled, 4-Way Crossover Study To Evaluate The Effect Of A Multiple Oral Dose of PF-00232798 On Qt Intervals In Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 22 Dec 2010
At a glance
- Drugs Moxifloxacin; PF 232798
- Indications Bacterial infections; HIV infections
- Focus Adverse reactions
- 22 Dec 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Nov 2010 Actual initiation date (Jul 2010) added as reported by ClinicalTrials.gov.
- 05 Aug 2010 Actual initiation date (Jun 2010) added as reported by ClinicalTrials.gov.